- Home
- RYDE vs XOMAP Comparison
RYDE vs XOMAP Comparison
Compare RYDE & XOMAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RYDE
- XOMAP
- Stock Information
- Founded
- RYDE 2014
- XOMAP N/A
- Country
- RYDE Singapore
- XOMAP United States
- Employees
- RYDE N/A
- XOMAP 13
- Industry
- RYDE
- XOMAP Biotechnology: Pharmaceutical Preparations
- Sector
- RYDE
- XOMAP Health Care
- Exchange
- RYDE NYSE
- XOMAP Nasdaq
- Market Cap
- RYDE N/A
- XOMAP N/A
- IPO Year
- RYDE 2024
- XOMAP N/A
- Fundamental
- Price
- RYDE $0.23
- XOMAP $25.69
- Analyst Decision
- RYDE Strong Buy
- XOMAP
- Analyst Count
- RYDE 1
- XOMAP 0
- Target Price
- RYDE $9.00
- XOMAP N/A
- AVG Volume (30 Days)
- RYDE 88.7K
- XOMAP N/A
- Earning Date
- RYDE 05-21-2025
- XOMAP N/A
- Dividend Yield
- RYDE N/A
- XOMAP N/A
- EPS Growth
- RYDE N/A
- XOMAP N/A
- EPS
- RYDE N/A
- XOMAP N/A
- Revenue
- RYDE $5,761,982.00
- XOMAP N/A
- Revenue This Year
- RYDE $2.61
- XOMAP N/A
- Revenue Next Year
- RYDE $21.90
- XOMAP N/A
- P/E Ratio
- RYDE N/A
- XOMAP N/A
- Revenue Growth
- RYDE N/A
- XOMAP N/A
- 52 Week Low
- RYDE $0.24
- XOMAP N/A
- 52 Week High
- RYDE $22.49
- XOMAP N/A
- Technical
- Relative Strength Index (RSI)
- RYDE N/A
- XOMAP 43.38
- Support Level
- RYDE N/A
- XOMAP $25.00
- Resistance Level
- RYDE N/A
- XOMAP $26.09
- Average True Range (ATR)
- RYDE 0.00
- XOMAP 0.14
- MACD
- RYDE 0.00
- XOMAP 0.00
- Stochastic Oscillator
- RYDE 0.00
- XOMAP 45.87
About XOMAP XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.